source
- Rezera files for IPO to fund NLRP3 peripheral artery disease programRezera, which rebranded from NodThera earlier this year, has entered the queue for an initial public offering. The filing, submitted on Wednesday, is intended to raise capital to support the compa…
- Paragon spinout Velaris Therapeutics goes public via reverse merger with Alaunos, raising $350 millionParagon Labs, a biotechnology incubator, announced that its latest spinout, Velaris Therapeutics, became a public company through a reverse merger with Alaunos Therapeutics. The transaction places…